Pharmatalkradio

At the Conference Forum's 2015 Chief Medical Officer's Summit in Boston, David Schenkein, MD, CEO, Agios provided a warm and personal keynote sharing his journey as a Physican CEO. In this recording of the session, gain an insight into Dr Schenkein's views on leadership in running a biotech company and more specifically: The journeyThe people and mentorshipsPrioritizing resourcesSuccesses and failuresOvercoming hurdlesStrategic partnershipsBusiness planningAudience Q&A This is a great session for leadership and aspiring leadership in life sciences and beyond. The Chief Medical Officer West Summit is this November 9-10 in the San Francisco area. See www.theconferenceforum.org for speaker line up and agenda information. The CMO West conference is dedicated to addressing the unique challenges faced by CMOs and their staff in managing R&D in emerging biotechs. PharmaTalkRadio is a non-profit program organized and supported by the Conference Forum to give easy and free access of helpful information to al

Clinical Air Episode #14 is pleased to present a discussion on Consumer Electronics in Clinical Research.Craig Lipset, Head of Clinical Innovation R&D at Pfizer welcomes guests from Rebar Interactive and Eli Lilly to address and explore an update on what's available, what's capable and what's working with consumer electronics in clinical research. We explore topics including, but not limited to: How to scale new toolsThe level of validation of different instrumentsThe impact of tools like the Apple Research KitWhat future apps will offer Hosted by Craig Lipset, Head of Clinical Innovation, R&D, Pfizer Guests: Rahlyn Gossen, Founder, Rebar Interactive Michael Luker, Director, Clinical Innovation, Eli Lilly Katherine Vandebelt, Senior Director, Clinical Development Innovation, Eli Lilly *Please note this session has some background sound interference at the start of the program.

The last 30 years of Immuno-Oncology research have provided strong evidence that tumors do recognize the immune system and their development can be stopped or controlled long term. Given the impressive survival data over the past five years, it is not surprising that Immuno-Oncology is arguably the most exciting area in the advancement of science and patient care today.  However, with all research, there are plenty of challenges and to get a better understanding of this innovative approach to cancer research, we are pleased to welcome to the program, James Gulley, MD, PhD of the National CancerInstitute and Roy Baynes, MD, PhDat Merck Research Labs. Joining Drs Gulley and Baynes is Kate Woda, Director of theIO360 conference taking place at Columbia University Faculty House on June 29-30 in NYC. Host: Valerie Bowling, Producer, Pharma Talk Radio Guests: James Gulley, MD, PhD, Head, Immunotherapy Section, Director, Medical Oncology Service, Office of the Clinical Director, Center for Cancer Research, Natio

Design Thinking is a human centered approach to innovation that helps uncover the sweet spot of opportunity where the needs of people, the possibilities of technology and the requirements for business success all converge. The application of the Design Thinking methodology (originating out of Stanford’s d.School) as a new approach to looking at solutions can lead to disruptive innovation in clinical trials for drug development. It allows for designing new ways of working, including the needs, challenges and insights about the complex world we work in.   In this discussion, we introduce the basic principals of Design Thinking and an understanding of how the methodology teaches empathy for the end user (the patients). We explore its ability to reframe questions and unleash innovative thinking as well as the "downside" of creative tension. Most importantly, we address how Design Thinking can drive more successful trials.   Hosted by Valerie Bowling, Executive Director of the Conference Forum, guests include:

In September 2012, TransCelerate Biopharma launched with the aim of simplifying and accelerating the delivery of innovative medicines to patients.  What progress has really been made and what are the realistic goals for 2015? In our 2015 kick off radio show, Clinical Air Episode #13, host Craig Lipset, Head of Clinical Innovation, R&D, Pfizer talks with Dalvir Gill, PhD, CEO of Transcelerate and Andy Lee, MD, SVP, Head of Global Clinical Trial Operations at Merck. In this frank discussion, we learn: What’s working well and changes for 2015?Is Tanscelerate performing better or differently from other collaborations?How have engagements with outside organizations advanced?  Where do gaps remain?How are new areas selected and scope defined?Thoughts on implementing new ideasNew role for CROsWhat deliverables does Tanscelerate anticipate for 2015?  

Since the FDA and EMA published their current thinking on clinical oversight and risk-based monitoring (RBM) strategies, the topic has received a magnitude of attention, commanding column inches, webinar discussions and industry conferences. With so much discussion going on, it is unsurprising that many sponsors are feeling out in the cold when it comes to identifying how to practically implement RBM strategies within study designs. As data quality matters most in determining study success and ensuring patient safety, the latest recommendations have created growing demand for solutions that simplify the transition to risk-based techniques. In this program, our guests discuss how emerging technologies and Central Statistical Monitoring (CSM) now present more practical means of implementing successful RBM strategies. Both Sanofi and Novartis will provide a large pharma perspective on making the move to RBM. Host: Valerie Bowling, Executive Director, The Conference Forum Guests: Marc Buyse, Founder, Internat

In Clinical Air Episode #12, Craig Lipset, Head of Clinical Innovation, R&D, Pfizer talks with Marc Sluijs, Director Life Science Business Development at Oracle Health Sciences.  Marc shares his thoughts on the digital health space and where technology is heading in clinical trials. In this informal discussion, Craig and Marc also cover how digital technologies can better serve patients as well as tips on keeping tabs on this rapidly moving space and what can disrupt pharma?  Host Craig Lipset Head of Clinical Innovation, R&D Pfizer Guest Marc Sluijs Director Life Science Business Development Oracle Health Sciences Producer Valerie Bowling Executive Director The Conference Forum

Donald Jones, Chief Digital Officer, Scripps Translational Science Institute talks with host Craig Lipset, Head of Clinical Innovation, R&D, Pfizer on what's happening with digital in drug development. Don discusses his thoughts on the evolution of new products with digital and the “digitazation” of tools for clinical trials. He also shares his thoughts on the biggest disruptors in pharma.  Don and Craig will be featured in an interview as well at DPharm: Disruptive Innovations to Advance Clinical Trials on September 11, 2014 in Boston. Host Craig Lipset Head of Clinical Innovation, R&D Pfizer Guest Donald Jones Chief Digital Officer Scripps Translational Science Institute & Founder & Chairman, Wireless Life Sciences Alliance Producer Valerie Bowling Executive Director The Conference Forum    

Join host, Craig H. Lipset, Head of Clinical Innovation, R&D, Pfizer lead a discussion on what it really means to partner with patients in clinical trials. Guests include: Jeri Burtchell, Founder, Partners in Research Regina Holliday, Artist and Medical Advocate For more information on Jeri's new launch, visit: Healthivibe.com and for Regina walking gallary, google Regina Holliday, walking gallary. For more information on the topic of Patients as Partners, visit www.theconferenceforum.org. The Conference Forum presented a program in March 2014 fully dedicated to understanding the journey a patient takes in clinical trials. Also take a look at Disruptive Innovations to Advance Clinical Trials scheduled for September 11-12, 2014 in Boston. This event addresses significant innovation to help improve a patients experience in a clinical trial.  

Join host, Craig Lipset, Head of Clinical Innovation, R&D, Pfizer lead a discussion onInvesting in the future of clinical research. Guests include: Todd Pietri, Co-Founder, Milestone Ventures Jeremy Sohn, Managing Director, MPM Capital  VC views on: Disruption in the clinical trial spaceEntrepreneursFinding opportunities (incubators and accelerators)Good sources of deal flowsInvesting in technology or people?MobileBig dataBeyond the pilland more.... Craig, Todd and Jeremy will also be speaking at Mobile@Dpharm on September 10th at the Farimont Copley Plaza hotel in Boston. This event helps drug developers get their arms around the mobile/digital clinical trial landscape and figure out: How mobile is innovating clinical trialsWhat parts of clinical trials mobile/digital technology is currently impactingHow mobile technology is making clinical trials cheaper, easier and more accurateHow mobile/digital is increasing the efficacy of drugsWhat the true value is to clinical trialsOpportunities There is an o

In Clinical Air episode # 8, host Craig Lipset, Head of Clinical Innovation, R&D, Pfizer hosts a show discussing investigators as partners in clinical research. Guests include: Christine Pierre, President, Society of Clinical Research Jacalyn Kent, Director, Clinical Development Information & Optimization, Eli Lilly Key topics include:  Misunderstandings around Remote Based Monitoring Training and communication challenges for remote site managersTranscelerate updateWhat are the real cost savings around RBM...are we just shifting costs?Real time data and how this should affect sites and paymentsReducing burdens to the sitesInvestigator turn over rate, making sites sustainable      

In 2013 Pfizer launched the Pfizer Blue Button Project, a first-of-it’s-kind initiative enabling patients who have participated in clinical trials the opportunity to download their individual clinical data.  Using the Blue Button standard launched by the White House, patients will be empowered to use the data to improve their overall health and wellness, from sharing with healthcare providers to powering clinical risk assessments.  In this show, our host Craig Lipset, Head of Clinical Innovation, R&D, Pfizer speaks to the leaders behind these initiatives to find out why they launched, initial learnings, and where the projects may go if successful. Also joining Craig is Thomas Krohn, Business Lead for the Lilly Clinical Open Innovation Team.  Host:   Craig Lipset, Head of Clinical Innovation, R&D, Pfizer  Guests: Adam Dole, Presidential Innovation Fellow, The White House Thomas Krohn, Business Lead for the Lilly Clinical Open Innovation Team Jennifer Wulff, Director, Clinical Innovation, Pfizer

How a patient experiences a clinical trial is changing. Access, ease, efficiencey, safety and better quality data collection are the target goals. This episode features some of the emerging technologies together with a discussion on the opportunities and challenges to include patient access, recruitment and retention. Predictions for 2014 are shared by our guests. Host: Craig H. Lipset, MBA Head of Clinical Innovation, Worldwide Research and Development, Pfizer Inc. Guests: Tomasz Sablinski, MD, PhD Founder & CEO, Transparency Life Sciences Komathi Stem Senior Director, Product Development, Innovation Lead, Genentech, A Member of the Roche Group, United States  

Join guests Kerri Weingard, ANP, COO, Verified Clinical Trials and Susan Salgado, PhD, Founder, Hospitality Quotient as they identify the barriers and limitations in engaging patients in clinical trials. What we can do about it through communication and service? Hosted by Valerie Bowling, Executive Director, the Conference Forum, this episode addresses one of the hottest topics at the Patients as Partners event scheduled for March 3-4, 2014 in Philadelphia. For more information, visit www.theconferenceforum.org About our Guests: Susan Reilly Salgado, PhD founded Hospitality Quotient with Danny Meyer in 2010.  Hospitality Quotient offers customized advice and training to inspire, build and sustain a company culture of service in organizations across industries.  In addition to her PhD, Susan holds a BS and an MBA from Lehigh University. Susan has also served as an instructor in organizational behavior and business strategy at NYU and as a guest lecturer at Lehigh. Kerri Weingard is the chief operating offic

This episode provides a recap on what's happening with mobile/sensors in clinical trials especially as they affect patients. Host: Craig Lipset, Head of Clinical Innovation, R&D, Pfizer, Inc.  Guests: Tim Davis, CEO & Co-Founder, Exco InTouch Abbe Steel, Vice President of Patient & Physician Services, UBC 

Eli Lilly and Quintiles entered into a co-investment partnership to develop a new solution using computer-assisted designs that emphasize the improvement of scientific and operational outcomes of clinical trials. The results were shared at the DPharm 2013 event and project leaders from both companies will talk to our host Craig Lipset on how this formation is doing a year later. Also joining Craig is Jeff Lee, CEO, Omniscience to discuss featured news and trends in clinical trial innovation and in particular mobile applications. Host: Craig Lipset, MBA, Head of Clinical Innovation, R&D, Pfizer, Inc. Guests: Jeffrey Kasher, PhD, VP & COO, Eli Lilly & Company Jeff Lee, CEO, Omniscience Mobile Rick Sax, MD, SVP Clinical Design & Reporting Services, Quintiles  

A panel of executives from leading pharma and the venture capital community at the DPharm Disruptive Innovations conference recently awarded the 2013 Disruptive Innovator of the Year title to Medidata Solutions and Spaulding Clinical Research. They won for their collaboration on a novel study evaluating the impact of mobile and cloud-based technology on patient engagement for improved health outcomes in the diabetes community. Host Craig Lipset, Head of Clinical Innovation, R&D at Pfizer speaks with Dr. Andrew Lee of Sanofi on key takeaways from the 2013 DPharm conference along with the CEOs of  the winning companies to learn more about their collaboration. Guests: Andrew Lee, MD, SVP, Deputy Head of Clinical Sciences & Operations, Sanofi Glen De Vries, President of Medidata Solutions Randy Spaulding, Founder and CEO of Spaulding Clinical Research    

Join us in a discussion on serving patients in clinical trials. Making clinical trials more accessible for patients Emerging technologies / iPads and informed consent Disruption Headlines in the news Host: Craig Lipset, MBA Head of Clinical Innovation, R&D, Pfizer Inc. Guests: Andreas Koester, MD, PhD VP, Clinical Trial Innovation & External Alliances,  Janssen Anthony Costello, CEO, Mytrus

The CMO of a biotech is like no other job in the world. The CMO is not only responsible for delivering on clinical trials, but also is a key player in the company's fundraising efforts.   From the Chief Medical Officer Summit, please join co-chairs Dr. Greg Fiore, CMO of the The Medicines Company and Dr. Steven Zelenkofske, CMO of Regado together with opening presenter Dr. Tyler Martin, CMO & Founder of Great Plains Biotechnology, to discuss the role of the CMO and how to best manage it.  Topics include:  What should a CMO be focused on? Functioning with restrictive capital Supporting a CEO who does not have experience in the therapeutic area you are in charge of The great balancing act

Drs. Christopher Gallen, CEO at SK BioPharmaceuticals and Mitchell Katz, Executive Director, Medical Research Operations at Purdue Pharma, in a candid conversation on navigating the complexities of Global Clinical Trials and addressing topics including: Why global trials? Why are global trials so expensive? How are companies re-thinking global trials? What's happening with global outsourcing? Thoughts on emerging markets and patient recruitment What can we do to help mitigate the risks of global trials?